Table 11.
Distribution of Histologically-Confirmed Brain and Other Central Nervous System Tumors by WHO Grade Completeness, Treatment Information Completeness, and Major Histology Grouping, CBTRUS Statistical Report: U.S. Cancer Statistics – U.S. Cancer Statistics - NPCR and SEER, 2013-2017
| Histology | Number of Newly Diagnosed Tumors (2013-2017) | Histologically Confirmeda (%) | WHO Grade Completeness (%) | Assigned WHO Grade | Radiation Information Completenessc (%) | Surgical Extent of Resection Information Complete Completenessd (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Completeb | Incomplete | Not Applicable | I | II | III | IV | |||||
| Tumors of Neuroepithelial Tissue | 113,056 | 89.2% | 87.0% | 11.5% | 1.5% | 10.6% | 13.7% | 13.0% | 62.8% | 55.4% | 97.8% |
| Pilocytic Astrocytoma | 5,167 | 90.1% | 87.9% | 11.7% | 0.4% | 93.9% | 5.1% | 0.8% | 0.3% | 5.8% | 99.0% |
| Diffuse Astrocytoma | 7,428 | 92.8% | 86.0% | 13.8% | 0.1% | 3.3% | 67.5% | 17.9% | 11.2% | 50.1% | 97.4% |
| Anaplastic Astrocytoma | 7,116 | 99.3% | 95.6% | 4.4% | 0.1% | 0.1% | 1.2% | 90.1% | 8.6% | 77.6% | 99.1% |
| Unique Astrocytoma Variants | 1,123 | 75.4% | 77.7% | 22.1% | 0.2% | 21.0% | 54.0% | 20.1% | 5.0% | 21.0% | 97.8% |
| Malignant | 769 | 87.3% | 79.7% | 20.0% | 0.3% | 2.8% | 66.4% | 24.7% | 6.2% | 30.1% | 97.5% |
| Non-Malignant | 354 | 49.7% | 69.9% | 30.1% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 1.8% | 98.3% |
| Glioblastoma | 60,056 | 93.4% | 90.5% | 9.5% | 0.0% | 0.2% | 0.2% | 0.7% | 99.0% | 69.6% | 97.5% |
| Oligodendroglioma | 3,698 | 96.8% | 93.7% | 6.3% | 0.0% | 1.6% | 88.3% | 6.3% | 3.9% | 36.9% | 98.0% |
| Anaplastic Oligodendroglioma | 1,859 | 99.1% | 95.7% | 4.3% | 0.0% | 0.0% | 3.2% | 88.8% | 8.0% | 71.8% | 98.8% |
| Oligoastrocytic Tumors | 1,572 | 99.0% | 94.8% | 5.2% | 0.0% | 0.7% | 48.3% | 42.7% | 8.2% | 59.7% | 99.5% |
| Ependymal Tumors | 6,843 | 88.4% | 87.5% | 12.4% | 0.1% | 36.0% | 48.6% | 14.5% | 0.9% | 26.1% | 98.5% |
| Malignant | 3,972 | 93.6% | 90.2% | 9.7% | 0.1% | 2.5% | 73.5% | 22.7% | 1.3% | 38.5% | 98.7% |
| Non-Malignant | 2,871 | 81.2% | 83.1% | 16.8% | 0.0% | 93.9% | 5.6% | 0.3% | 0.3% | 8.7% | 98.2% |
| Glioma Malignant, NOS | 8,093 | 36.3% | 50.9% | 48.0% | 1.1% | 15.0% | 26.7% | 22.4% | 35.9% | 28.2% | 97.4% |
| Choroid Plexus Tumors | 827 | 88.0% | 77.2% | 22.8% | 0.0% | 64.2% | 19.3% | 15.9% | 0.7% | 4.7% | 98.1% |
| Malignant | 128 | 97.7% | 80.8% | 19.2% | 0.0% | 5.0% | 3.0% | 88.1% | 4.0% | 15.0% | 100.0% |
| Non-Malignant | 699 | 86.3% | 76.4% | 23.6% | 0.0% | 77.2% | 22.8% | 0.0% | 0.0% | 2.8% | 97.8% |
| Other Neuroepithelial Tumors | 107 | 94.4% | 57.4% | 41.6% | 1.0% | 8.6% | 55.2% | 24.1% | 12.1% | 39.4% | 97.5% |
| Malignant | 66 | 98.5% | 47.7% | 50.8% | 1.5% | 9.7% | 22.6% | 45.2% | 22.6% | 54.1% | 96.0% |
| Non-Malignant | 41 | 87.8% | 75.0% | 25.0% | 0.0% | 7.4% | 92.6% | 0.0% | 0.0% | 15.8% | 100.0% |
| Neuronal and Mixed Neuronal Glial Tumors | 4,934 | 92.2% | 65.4% | 18.1% | 16.5% | 81.0% | 15.1% | 3.2% | 0.6% | 15.5% | 98.4% |
| Malignant | 947 | 98.5% | 16.5% | 4.8% | 78.7% | 28.6% | 9.1% | 55.2% | 7.1% | 61.7% | 97.4% |
| Non-Malignant | 3,987 | 90.7% | 78.0% | 21.5% | 0.5% | 83.9% | 15.5% | 0.4% | 0.3% | 4.7% | 98.6% |
| Tumors of the Pineal Region | 787 | 77.5% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 40.9% | 98.3% |
| Malignant | 447 | 96.9% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 66.3% | 98.1% |
| Non-Malignant | 340 | 52.1% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 8.6% | 98.4% |
| Embryonal Tumors | 3,446 | 98.1% | 77.5% | 21.7% | 0.7% | 1.3% | 0.2% | 1.5% | 97.1% | 62.8% | 97.6% |
| Tumors of Cranial and Spinal Nerves | 35,600 | 49.7% | 36.4% | 63.6% | 0.0% | 99.2% | 0.5% | 0.2% | 0.2% | 17.4% | 98.3% |
| Nerve Sheath Tumors | 35,560 | 49.7% | 36.4% | 63.6% | 0.0% | 99.2% | 0.5% | 0.2% | 0.2% | 17.4% | 98.3% |
| Malignant | 223 | 78.9% | 22.7% | 77.3% | 0.0% | 57.5% | 15.0% | 15.0% | 12.5% | 34.7% | 85.7% |
| Non-Malignant | 35,337 | 49.6% | 36.5% | 63.5% | 0.0% | 99.4% | 0.4% | 0.1% | 0.1% | 17.3% | 98.3% |
| Other Tumors of Cranial and Spinal Nerves | 40 | 42.5% | 23.5% | 76.5% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 2.5% | 100.0% |
| Tumors of Meninges | 163,619 | 40.1% | 79.9% | 20.1% | 0.1% | 80.1% | 17.7% | 2.1% | 0.2% | 7.2% | 97.7% |
| Meningioma | 159,038 | 38.8% | 81.3% | 18.7% | 0.0% | 80.3% | 17.9% | 1.6% | 0.1% | 6.9% | 97.6% |
| Malignant | 1,750 | 79.2% | 85.3% | 14.6% | 0.1% | 21.2% | 17.2% | 60.6% | 1.1% | 38.8% | 84.9% |
| Non-Malignant | 157,288 | 38.3% | 81.2% | 18.8% | 0.0% | 81.7% | 18.0% | 0.2% | 0.1% | 6.6% | 97.7% |
| Mesenchymal Tumors | 1,462 | 74.7% | 55.7% | 43.8% | 0.5% | 9.4% | 43.3% | 42.9% | 4.4% | 32.4% | 98.1% |
| Primary Melanocytic Lesions | 108 | 88.9% | 12.5% | 82.3% | 5.2% | 58.3% | 33.3% | 0.0% | 8.3% | 45.4% | 94.7% |
| Other Neoplasms Related to the Meninges | 3,011 | 91.9% | 59.1% | 39.9% | 1.0% | 99.3% | 0.4% | 0.1% | 0.2% | 6.9% | 98.4% |
| Lymphoma and Hematopoietic Neoplasms | 8,150 | 94.9% | 7.7% | 90.7% | 1.6% | 100.0% | 0.0% | 0.0% | 0.0% | 20.7% | 99.1% |
| Lymphoma | 7,919 | 95.0% | 8.0% | 91.3% | 0.7% | 100.0% | 0.0% | 0.0% | 0.0% | 20.3% | 99.1% |
| Other Hematopoietic Neoplasms | 231 | 88.7% | 0.9% | 79.6% | 19.5% | 100.0% | 0.0% | 0.0% | 0.0% | 33.5% | 99.2% |
| Germ Cell Tumors and Cysts | 1,585 | 81.1% | 3.8% | 53.7% | 42.5% | 18.4% | 6.1% | 6.1% | 69.4% | 47.9% | 98.2% |
| Germ Cell Tumors, Cysts and Heterotopias | 1,585 | 81.1% | 3.8% | 53.7% | 42.5% | 18.4% | 6.1% | 6.1% | 69.4% | 47.9% | 98.2% |
| Malignant | 1,095 | 88.0% | 4.4% | 42.5% | 53.1% | 4.8% | 7.1% | 7.1% | 81.0% | 67.9% | 98.9% |
| Non-Malignant | 490 | 65.7% | 2.2% | 87.0% | 10.9% | 100.0% | 0.0% | 0.0% | 0.0% | 2.8% | 96.6% |
| Tumors of Sellar Region | 73,340 | 46.9% | 0.5% | 0.5% | 99.0% | 100.0% | 0.0% | 0.0% | 0.0% | 3.0% | 97.7% |
| Tumors of the Pituitary | 70,211 | 45.2% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 2.2% | 97.7% |
| Malignant | 142 | 66.9% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 19.2% | 84.8% |
| Non-Malignant | 70,069 | 45.2% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 2.2% | 97.7% |
| Craniopharyngioma | 3,129 | 84.0% | 6.4% | 6.5% | 87.1% | 100.0% | 0.0% | 0.0% | 0.0% | 22.0% | 97.9% |
| Unclassified Tumors | 20,061 | 17.4% | 4.7% | 87.0% | 8.3% | 63.6% | 9.1% | 9.7% | 17.6% | 3.9% | 69.8% |
| Hemangioma | 5,731 | 29.6% | 2.5% | 97.1% | 0.4% | 88.4% | 7.0% | 4.7% | 0.0% | 2.2% | 97.6% |
| Neoplasm Unspecified | 14,136 | 12.2% | 6.4% | 78.0% | 15.6% | 56.4% | 10.9% | 10.9% | 21.8% | 4.8% | 59.9% |
| Malignant | 6,587 | 8.2% | 8.5% | 85.8% | 5.7% | 17.4% | 13.0% | 23.9% | 45.7% | 9.0% | 42.5% |
| Non-Malignant | 7,549 | 15.6% | 5.4% | 74.5% | 20.1% | 84.4% | 9.4% | 1.6% | 4.7% | 2.8% | 75.7% |
| All Other | 194 | 37.6% | 16.4% | 63.0% | 20.5% | 41.7% | 0.0% | 16.7% | 41.7% | 10.6% | 92.1% |
| TOTAL | 415,411 | 55.6% | 65.2% | 18.7% | 16.1% | 39.5% | 14.5% | 8.5% | 37.5% | 21.0% | 95.9% |
| Malignant | 123,484 | 85.5% | 83.9% | 14.1% | 2.0% | 6.0% | 13.8% | 14.6% | 65.5% | 55.1% | 92.1% |
| Non-Malignant | 291,927 | 43.0% | 50.2% | 22.4% | 27.4% | 84.1% | 15.4% | 0.3% | 0.1% | 6.8% | 97.1% |
a. Histologic confirmation includes tumors classified as diagnosis confirmed by: positive histology, positive cytology, positive histology plus – positive immunophenotyping and/or positive genetic studies, or positive microscopic confirmation, method not specified.
b. Completeness is defined as having an assigned code that corresponds with a WHO grade as defined by the American Joint Commission on Cancer’s Collaborative Staging schema.
c. Radiation is defined using a recoded variable based on NAACCR Item #1360 (http://datadictionary.naaccr.org/default.aspx?c=10#136). Completeness is defined as having a value other than ‘none’ or ‘unknown.’
d. Surgery is defined using a recoded variable based on NAACCR Item #1290 (http://datadictionary.naaccr.org/default.aspx?c=10#1290). Please see the SEER site-specific surgery codes for more information on coding for this variable (https://seer.cancer.gov/archive/tools/SEER2003.surg.prim.site.codes.pdf). Completeness is defined as having a value other than ‘unknown.’
- Percentages are not presented when category is not applicable.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; WHO, World Health Organization